PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-313.81%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
289.12%
SBC growth well above AXSM's 5.59%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-122.10%
Negative yoy working capital usage while AXSM is 0.00%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
113.90%
A yoy AP increase while AXSM is negative at -56.31%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-180.39%
Negative yoy usage while AXSM is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2618.61%
Some yoy increase while AXSM is negative at -19.79%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
17.02%
Operating cash flow growth at 50-75% of AXSM's 25.25%. Martin Whitman would worry about lagging operational liquidity vs. competitor.
-23.76%
Negative yoy CapEx while AXSM is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.76%
We reduce yoy invests while AXSM stands at 96.15%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-278.89%
Both yoy lines negative, with AXSM at -29.18%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.